Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Current Liabilities (2018 - 2025)

X4 Pharmaceuticals' Total Current Liabilities history spans 8 years, with the latest figure at $25.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 21.66% year-over-year to $25.8 million; the TTM value through Dec 2025 reached $25.8 million, down 21.66%, while the annual FY2025 figure was $25.8 million, 21.66% down from the prior year.
  • Total Current Liabilities reached $25.8 million in Q4 2025 per XFOR's latest filing, up from $23.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $32.9 million in Q4 2024 to a low of $13.1 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $22.3 million, with a median of $22.9 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 117.0% in 2022, then fell 21.66% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $14.0 million in 2021, then soared by 59.2% to $22.3 million in 2022, then increased by 2.41% to $22.9 million in 2023, then soared by 43.81% to $32.9 million in 2024, then dropped by 21.66% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Total Current Liabilities are $25.8 million (Q4 2025), $23.5 million (Q3 2025), and $22.9 million (Q2 2025).